2023 American Society of Hematology Annual Meeting Abstract

Type 1/like CALR mutation in momelotinib-treated patients with myelofibrosis is the most prominent predictor of drug survival and longevity without transplant

2023 American Society of Hematology Annual Meeting Abstract

Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

2023 American Society of Hematology Annual Meeting Abstract

ASXL1 mutation and leukocytosis undermine spleen response to pacritinib in myelofibrosis

2023 American Society of Hematology Annual Meeting Abstract

Clinical parameters, anemia, and spleen response in patients with MF-related anemia treated with luspatercept: Efficacy sub-analysis from the ACE-536-MF-001 study

2023 American Society of Hematology Annual Meeting Abstract

Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naive patients with myelofibrosis: Long term follow up from XPORT-MF-034 suggestive of disease modification

2023 American Society of Hematology Annual Meeting Abstract

TRANSFORM-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis

Frontiers in Oncology

Epigenetics in myeloproliferative neoplasms

Cancer Medicine

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia

Cancers

Prognostic significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in patients with myelofibrosis: A retrospective study

Turkish Journal of Hematology

The clinical impact of JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms